Sami Shousha
London, ENG SW72AZ, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 78 publications
Correction: Performance of a novel spectroscopy-based tool for adjuvant therapy decision-making in hormone receptor-positive breast cancer: a validation study.
Journal: Breast cancer research and treatment
Published: May 05, 2024
Clinicopathological Predictors of Positive Resection Margins in Breast-Conserving Surgery.
Journal: Annals of surgical oncology
Published: January 15, 2024
Testing of rapid evaporative mass spectrometry for histological tissue classification and molecular diagnostics in a multi-site study.
Journal: British journal of cancer
Published: October 13, 2023
Performance of a novel spectroscopy-based tool for adjuvant therapy decision-making in hormone receptor-positive breast cancer: a validation study.
Journal: Breast cancer research and treatment
Published: August 02, 2023
CD10 expression as a potential predictor of pathological complete response in ER-negative and triple-negative breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy.
Journal: Experimental and molecular pathology
Published: February 07, 2023
Author Correction: SREBP1 drives keratin-80-dependent cytoskeletal changes and invasive behavior in endocrine-resistant ERα breast cancer.
Journal: Nature communications
Published: August 21, 2019
Oncogenic EP300 can be targeted with inhibitors of aldo-keto reductases.
Journal: Biochemical pharmacology
Published: January 15, 2019
All Benign and Malignant Apocrine Breast Lesions Over-Express Claudin 1 and 3 and Are Negative for Claudin 4.
Journal: Pathology oncology research : POR
Published: June 22, 2018
Correction to: Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer.
Journal: Breast cancer research and treatment
Published: January 07, 2018
Enhancer mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer.
Journal: Nature medicine
Published: September 25, 2017
Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer.
Journal: Breast cancer research and treatment
Published: February 06, 2017
Last Updated: 09/26/2026